

Brice Pastor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9592469/publications.pdf>

Version: 2024-02-01

12
papers

687
citations

1040056

9
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

1271
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood contains circulating cell-free respiratory competent mitochondria. <i>FASEB Journal</i> , 2020, 34, 3616-3630.	0.5	255
2	Quantifying circulating cell-free DNA in humans. <i>Scientific Reports</i> , 2019, 9, 5220.	3.3	145
3	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	7.0	70
4	Recent advances in circulating nucleic acids in oncology. <i>Annals of Oncology</i> , 2019, 30, 374-384.	1.2	69
5	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	7.0	50
6	Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. <i>JCI Insight</i> , 2021, 6, .	5.0	47
7	Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124483.	5.9	21
8	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. <i>IScience</i> , 2022, 25, 103826.	4.1	13
9	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021, 15, 2401-2411.	4.6	11
10	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 564.	2.6	3
11	UCGI 28 Panirinix: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. <i>Annals of Oncology</i> , 2018, 29, viii204.	1.2	2
12	Reply to Comment on: "Hypoxia differently modulates the release of mitochondrial and nuclear DNA". <i>British Journal of Cancer</i> , 2021, 124, 2037-2038.	6.4	0